KBC Group NV trimmed its holdings in Eli Lilly and Co (NYSE:LLY) by 31.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 537,918 shares of the company’s stock after selling 244,519 shares during the quarter. KBC Group NV’s holdings in Eli Lilly and were worth $45,432,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Swiss National Bank raised its holdings in shares of Eli Lilly and by 0.4% during the 4th quarter. Swiss National Bank now owns 4,173,743 shares of the company’s stock worth $352,514,000 after acquiring an additional 16,300 shares in the last quarter. Reliant Investment Management LLC purchased a new stake in shares of Eli Lilly and during the 4th quarter worth approximately $2,912,000. Carmichael Hill & Associates Inc. purchased a new stake in shares of Eli Lilly and during the 4th quarter worth approximately $251,000. Bedel Financial Consulting Inc. purchased a new stake in shares of Eli Lilly and during the 4th quarter worth approximately $29,362,000. Finally, California Public Employees Retirement System raised its holdings in shares of Eli Lilly and by 5.0% during the 4th quarter. California Public Employees Retirement System now owns 2,657,112 shares of the company’s stock worth $224,420,000 after acquiring an additional 127,143 shares in the last quarter. Institutional investors and hedge funds own 76.45% of the company’s stock.

Shares of Eli Lilly and Co (LLY) opened at $76.23 on Friday. Eli Lilly and Co has a twelve month low of $73.69 and a twelve month high of $89.09. The firm has a market capitalization of $81,712.27, a price-to-earnings ratio of -381.13, a P/E/G ratio of 1.36 and a beta of 0.23. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. During the same quarter in the prior year, the firm posted $0.95 EPS. Eli Lilly and’s quarterly revenue was up 7.0% compared to the same quarter last year. equities analysts forecast that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.95%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is presently -1,039.95%.

In related news, SVP Susan Mahony sold 36,585 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now owns 54,885 shares in the company, valued at approximately $4,729,989.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Donald A. Zakrowski sold 900 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the sale, the insider now owns 4,130 shares in the company, valued at approximately $334,901.70. The disclosure for this sale can be found here. Insiders have sold a total of 259,610 shares of company stock worth $22,727,406 in the last 90 days. 0.20% of the stock is currently owned by insiders.

LLY has been the topic of several recent research reports. Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday, January 16th. Goldman Sachs Group cut Eli Lilly and from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $86.98 to $95.00 in a report on Tuesday, January 16th. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and upped their price objective for the stock from $85.52 to $115.00 in a report on Friday, January 5th. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, December 5th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a report on Friday, October 13th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $92.02.

ILLEGAL ACTIVITY WARNING: This piece was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://theolympiareport.com/2018/02/10/eli-lilly-and-co-lly-holdings-trimmed-by-kbc-group-nv.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.